Given this pattern in weight loss following treatment with an AOM, anti-obesity therapy should be conceptualized as initiating weight loss followed by establishing a new weight plateau and assisting in maintaining this weight in the long term [9, 11]
This includes: The Science of GLP-1 Agonists: Semaglutide and Tirzepatide The medications at the forefront of the FAAs updated weight loss policies, particularly semaglutide and tirzepatide, are revolutionizing how we approach weight management
Research shows that GLP-1 receptor agonists reduce food cravings and snacking frequency independent of conscious dieting effort
PlexusDx offers oral semaglutide at $289/mo month-to-month, or from $249/mo on the 6-month plan and oral tirzepatide at $349/mo (or $279/mo on the 6-month plan)
Safety, Tolerability, and Who Should Consider Each Option Both medications carry FDA warnings regarding thyroid C-cell tumors (contraindicated in personal or family history of medullary thyroid cancer) and pancreatitis risk